Skip to main content

Table 1 Description of the main clinical and laboratory features at baseline and after 6 months of 130 mmol Na CAPD

From: Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study

 

Patient 1

Patient 2

Baseline

130-Na CAPD

Baseline

130-Na CAPD

Creatinine (mg/dL)

5.14

5.17

5.28

6.72

Measured GFR (mL/min/1.73 m2)

6.0

6.3

9.9

6.2

Urine volume (mL/24 h)

1300

1600

1700

1600

Body weight (kg)

56.0 ± 0.4a

56.7 ± 0.3b

69.0 ± 0.7a

70.3 ± 0.6b

Ultrafiltration (mL/24 h)

330 ± 126a

365 ± 113b

450 ± 135a

485 ± 132b

Total Ktv

1.65/week

1.68/week

1.75/week

1.80/week

Serum sodium (mmol/L)

137

137

138

139

Serum potassium (mmol/L)

4.9

4.3

4.1

3.8

Serum Urea (mg/dL)

173

177

144

161

Serum Hemoglobin (mg/dL)

11.6

12.4

11.5

10.4

Serum Albumin (g/L)

3.3

3.6

3.9

3.5

Serum PTH (pg/mL)

297

250

589

357

Home Systolic BP (mmHg)

147 ± 7a

140 ± 9b

135 ± 5a

120 ± 3b

Home Diastolic BP (mmHg)

78 ± 5a

73 ± 5b

85 ± 4a

70 ± 3b

  1. aMean of all available measurements before the switch (N = 86); bMean of all home measurements after the switch (N = 115). All BP measurements were performed by automatic sphygmomanometer (Omron M3®). Patients were trained according to EURECA-m, ERA-EDTA and ESH guidelines [16]. Body weight was gauged by automatic scale. Ultrafiltration was calculated by difference in the weight of dialysate before and after each dwell